BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28471719)

  • 1. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
    Park JR; Bagatell R; Cohn SL; Pearson AD; Villablanca JG; Berthold F; Burchill S; Boubaker A; McHugh K; Nuchtern JG; London WB; Seibel NL; Lindwasser OW; Maris JM; Brock P; Schleiermacher G; Ladenstein R; Matthay KK; Valteau-Couanet D
    J Clin Oncol; 2017 Aug; 35(22):2580-2587. PubMed ID: 28471719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new international neuroblastoma response criteria.
    Orr KE; McHugh K
    Pediatr Radiol; 2019 Oct; 49(11):1433-1440. PubMed ID: 31620844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
    Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
    J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.
    Matthay KK; Shulkin B; Ladenstein R; Michon J; Giammarile F; Lewington V; Pearson AD; Cohn SL
    Br J Cancer; 2010 Apr; 102(9):1319-26. PubMed ID: 20424613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma.
    Shulkin BL; Shapiro B; Hutchinson RJ
    J Nucl Med; 1992 Oct; 33(10):1735-40. PubMed ID: 1403138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
    Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
    Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
    Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
    Park JR; Villablanca JG; Hero B; Kushner BH; Wheatley K; Beiske KH; Ladenstein RL; Baruchel S; Macy ME; Moreno L; Seibel NL; Pearson AD; Matthay KK; Valteau-Couanet D
    Cancer; 2022 Nov; 128(21):3775-3783. PubMed ID: 36101004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal FDG and MIBG Activity in the Bones in a Patient With Neuroblastoma Without Detectable Primary Tumor.
    Zhang W; Zhuang H; Servaes S
    Clin Nucl Med; 2016 Aug; 41(8):632-3. PubMed ID: 26825196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.
    Sharp SE; Shulkin BL; Gelfand MJ; Salisbury S; Furman WL
    J Nucl Med; 2009 Aug; 50(8):1237-43. PubMed ID: 19617326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of morphological/immunohistochemical versus nuclear medicine imaging modalities in detecting metastatic bone and/or marrow deposits in neuroblastoma patients.
    Zaher Ael-S; Zaher AM; Moneer MM; El Gamal BM
    J Egypt Natl Canc Inst; 2011 Jun; 23(2):79-88. PubMed ID: 22099965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the utility of
    Gauguet JM; Pace-Emerson T; Grant FD; Shusterman S; DuBois SG; Frazier AL; Voss SD
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
    Schmidt M; Simon T; Hero B; Schicha H; Berthold F
    Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can MIBG scan replace the need for bone marrow assessment at diagnosis and reassessment in stage 4 neuroblastomas?
    Frappaz D; Combaret V; Desuzinges C; Bouffet E; Bailly C; Favrot MC; Philip T
    Bull Cancer; 2004; 91(7-8):E253-60. PubMed ID: 15381463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology.
    Hadj-Djilani NL; Lebtahi NE; Delaloye AB; Laurini R; Beck D
    Eur J Nucl Med; 1995 Apr; 22(4):322-9. PubMed ID: 7607262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal assessment in neuroblastoma--the pitfalls of iodine-123-MIBG scans.
    Gordon I; Peters AM; Gutman A; Morony S; Dicks-Mireaux C; Pritchard J
    J Nucl Med; 1990 Feb; 31(2):129-34. PubMed ID: 2313350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
    Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.